海珠益肝化纤方治疗肝纤维化的临床疗效观察
|
摘要
目的:观察海珠益肝化纤方治疗肝纤维化(肝胆湿热证)的临床疗效。方法:将符合诊断标准的80例患者随机分为治疗组和对照组,治疗组使用海珠益肝化纤方治疗,对照组使用水飞蓟素片治疗。比较治疗前后临床症状、肝功能(AST、ALT、TBIL、A、A/G)、肝纤指标(PⅢP、CIV、LN、HA)、FIB-4指数、肝脏硬度值的变化。结果:治疗组临床症状明显改善,与对照比较有显著差异(P<0.05),治疗组与对照组治疗后AST、ALT、TBIL、A、A/G、PⅢP、CIV、LN、HA、FIB-4指数、肝脏硬度值均明显改善(P<0.05),组间比较,治疗组AST、ALT、TBIL、A、A/G、PⅢP、CIV、LN、HA、FIB-4指数、肝脏硬度值改善程度优于对照组(P<0.05)。结论:海珠益肝化纤方治疗肝纤维化(肝胆湿热证)在改善症状、肝功能、肝纤指标、FIB-4指数、肝脏硬度值方面均优于水飞蓟素片。
Objective: To observe the clinical efficacy of Haizhu Yigan Huaxian Docoction in treating liver fibrosis(hepatobiliary damp-heat syndrome). Methods: 80 patients who meet the diagnostic criteria were randomly divided into treatment group and control group. The treatment group was treated with Haizhu Yigan Huaxian Docoction, while the control group was treated with silymarin tablets. The changes of clinical symptoms, liver function(AST, ALT, TBIL, A, A/G), liver fibrosis index(PⅢP, CIV, LN, HA), FIB-4 index and liver hardness were compared before and after treatment. Results: The clinical symptoms in the treatment group were significantly improved compared with the control group(P<0.05). After treatment, the AST, ALT, TBIL, A, A/G, PⅢP, CIV, LN, HA, FIB-4 of the two groups were all significantly improved(P<0.05), and these indexes of the treatment group were better than that of the control group(P<0.05).Conclusion: Haizhu Yigan Huaxian Docoction on treating liver fibrosis can in improving symptoms, liver function, liver fiber index, FIB-4 index and its clinical efficacy is better than that of silymarin tablets.
Objective: To observe the clinical efficacy of Haizhu Yigan Huaxian Docoction in treating liver fibrosis(hepatobiliary damp-heat syndrome). Methods: 80 patients who meet the diagnostic criteria were randomly divided into treatment group and control group. The treatment group was treated with Haizhu Yigan Huaxian Docoction, while the control group was treated with silymarin tablets. The changes of clinical symptoms, liver function(AST, ALT, TBIL, A, A/G), liver fibrosis index(PⅢP, CIV, LN, HA), FIB-4 index and liver hardness were compared before and after treatment. Results: The clinical symptoms in the treatment group were significantly improved compared with the control group(P<0.05). After treatment, the AST, ALT, TBIL, A, A/G, PⅢP, CIV, LN, HA, FIB-4 of the two groups were all significantly improved(P<0.05), and these indexes of the treatment group were better than that of the control group(P<0.05).Conclusion: Haizhu Yigan Huaxian Docoction on treating liver fibrosis can in improving symptoms, liver function, liver fiber index, FIB-4 index and its clinical efficacy is better than that of silymarin tablets.
引文
[1]肝纤维化诊断及疗效评估共识[J].药品评价,2007(4):265-266.
[2]肝纤维化中西医结合诊疗指南[J].中国中西医结合杂志,2006(11):1052-1056.
[3]李隽,韩涛.2015中国慢性乙型肝炎指南更新要点解析[J].临床荟萃,2016,31(7):701-704.
[4]肝脏硬度评估小组.瞬时弹性成像技术诊断肝纤维化专家意见[J].中华肝脏病杂志,2013(21):420-423.
[5]汪美凤,平键.肝星状细胞主要信号转导通路与肝纤维化的关系[J].实用肝脏病杂志,2010,13(6):466-469.
[6]Hernandezgea V,Friedman S L.Pathogenesis of Liver Fibrosis[J].Annu Rev Pathol,2011,6(1):425-456.
[7]Sohrabpour A A,Mohamadnejad M,Malekzadeh R.Review article:the reversibility of cirrhosis[J].Alimentary Pharmacology&Therapeutics,2012,36(9):824-832.
[2]肝纤维化中西医结合诊疗指南[J].中国中西医结合杂志,2006(11):1052-1056.
[3]李隽,韩涛.2015中国慢性乙型肝炎指南更新要点解析[J].临床荟萃,2016,31(7):701-704.
[4]肝脏硬度评估小组.瞬时弹性成像技术诊断肝纤维化专家意见[J].中华肝脏病杂志,2013(21):420-423.
[5]汪美凤,平键.肝星状细胞主要信号转导通路与肝纤维化的关系[J].实用肝脏病杂志,2010,13(6):466-469.
[6]Hernandezgea V,Friedman S L.Pathogenesis of Liver Fibrosis[J].Annu Rev Pathol,2011,6(1):425-456.
[7]Sohrabpour A A,Mohamadnejad M,Malekzadeh R.Review article:the reversibility of cirrhosis[J].Alimentary Pharmacology&Therapeutics,2012,36(9):824-832.